Investors

AbbVie Biotech Ventures, Inc.

AbbVie Biotech Ventures, Inc. (ABVI) is a subsidiary of AbbVie dedicated to making venture capital investments in emerging biotech and pharmaceutical companies.

Unlike traditional venture capital firms, ABVI characterizes an investment’s success by its potential to significantly increase AbbVie’s strategic growth, and not solely by its financial return.





Alta Partners

Alta partners is a leading venture capital firm in life sciences, funding over 120 companies in the industry since 1996. Our diverse and integrated team brings together a powerful depth of knowledge and experience, delivering tangible results for our companies and our investors.

We are committed to building successful businesses through deep collaborative partnerships with outstanding entrepreneurs. We are long-term investors and believe that it is critical to be a value-added investor by actively working with portfolio company management teams to help build market-leading companies.

Sutter Hill Ventures

Sutter Hill Ventures has financed technology-based start-ups and assisted entrepreneurs in building market-leading companies since 1964. Through our decades of experience, we have developed strong industry networks, considerable operating and venture capital experience, and an understanding of the challenges that early-stage and high-growth companies face.

We offer expertise in developing business strategy and partnerships, building management teams, and financing companies in both public and private markets.


TPG

TPG Growth Biotech is a leading global private investment firm with over $30 billion of capital under management. We manage a family of funds including private equity, venture capital and public equity and debt investing. Since the firm’s founding in 1992, our investment philosophy has been to create value by investing in change – change created by industry trends, economic cycles or specific company circumstances.

Our tradition of providing unique investment insight and value-added operating capabilities to companies undergoing change, as well as our comfort in dealing with complexity and distressed companies, differentiates us from many traditional private investment firms.